USRE46555E1 - Deuterated catecholamine derivatives and medicaments comprising said compounds - Google Patents

Deuterated catecholamine derivatives and medicaments comprising said compounds Download PDF

Info

Publication number
USRE46555E1
USRE46555E1 US14/464,568 US200714464568A USRE46555E US RE46555 E1 USRE46555 E1 US RE46555E1 US 200714464568 A US200714464568 A US 200714464568A US RE46555 E USRE46555 E US RE46555E
Authority
US
United States
Prior art keywords
dihydroxyphenyl
amino
propionic acid
dideutero
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/464,568
Other languages
English (en)
Inventor
Rudolf-Giesbert Alken
Frank Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Priority to US14/464,568 priority Critical patent/USRE46555E1/en
Assigned to IMPHAR AKTIENGESELLSCHAFT reassignment IMPHAR AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH & DEVELOPMENT SERVICES
Assigned to RATIOPHARM GMBH reassignment RATIOPHARM GMBH MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: IMPHAR AKTIENGESELLSCHAFT, RATIOPHARM GMBH
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RATIOPHARM GMBH
Application granted granted Critical
Publication of USRE46555E1 publication Critical patent/USRE46555E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds.
  • L-dopa levodopa
  • carboxylic acid esters are utilized, among other things, for the treatment of Parkinson's disease and restless leg syndrome.
  • a pharmaceutical which contains levodopa is, for example, Dopaflex®.
  • L-dopa acts on the dopamine concentration in neurons of the brain. Unlike dopamine itself, it can pass through the blood-brain barrier and is converted to dopamine in the brain.
  • levodopa is administered in combination with active additives in pharmaceuticals.
  • Combinations of levodopa are used with peripheral decarboxylase inhibitors, with inhibitors of the enzyme catechol-O-methyltransferase (COMT), with inhibitors of the enzyme monoamine oxidase (MAO) and with dopamine ⁇ -hydroxylase inhibitors.
  • CCT catechol-O-methyltransferase
  • MAO monoamine oxidase
  • dopamine ⁇ -hydroxylase inhibitors dopamine ⁇ -hydroxylase inhibitors.
  • the decarboxylase inhibitors used are, for example: D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxybenzyl) hydrazide, glycine-2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine-2-(2,3,4-trihydroxybenzyl) hydrazide.
  • combination preparations of levodopa and decarboxylase inhibitors include, among others: Madopar® (levodopa and benserazide hydrochloride) as well as Nacom® (levodopa and carbidopa).
  • COMT inhibitors examples include entacapone (Comtan®) and cabergoline and frequently used MAO inhibitors are selegiline hydrochloride, moclobemide and tranylcypromine.
  • Calcium 5-butyl picolinate and calcium 5-pentyl picolinate are described as inhibitors for dopamine- ⁇ -hydroxylase (DE 2,049,115).
  • WO-A 2004/056724 discloses deuterated catecholamine having two deuterium atoms in the ⁇ -position. These compounds exhibit improved pharmacokinetic and/or pharmacodynamic properties with respect to undeuterated compounds and as compared to L-DOPA.
  • An object of the present invention is to prepare deuterated catecholamine derivatives, which have improved pharmacokinetic and/or pharmacodynamic properties when compared to compounds already known, as well as to prepare catecholamine derivatives, which can be utilized for the prophylaxis of psychoses including schizophrenia, and which can be used for producing pharmaceuticals for the prophylaxis of psychoses.
  • the deuterated catecholamine derivatives according to the invention have substantially better pharmacokinetic and/or pharmacodynamic properties than the undeuterated compounds and the ⁇ , ⁇ -di-deuterated compounds known in the art and that they can also be utilized for the prophylaxis of psychoses and can be used for producing pharmaceuticals for the prophylaxis of psychoses.
  • Groups that are easily hydrolytically or enzymatically cleavable under physiological conditions are known to one skilled in the art.
  • the groups are common protective groups which are used in synthesis or that are such protective groups which lead to so-called prodrugs.
  • These groups may be selected from the group comprising methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 to C 6 -alkyl, that may be branched or unbranched, or C 5 to C 6 cycloalkyl, deuterated or partly deuterated C 1 to C 6 alkyl, that may be branched or unbranched, or deuterated or partly deuterated C 5 to C 6 -cycloalkyl.
  • deuterated catecholamine derivatives according to formula 1, namely
  • Another embodiment of the invention is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine trans-port or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for the stimulation of the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy.
  • dopamine deficiency diseases or diseases which are based on disrupted tyrosine trans-port or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for the stimulation of the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis
  • Preferred is the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, in combination with an enzyme inhibitor or several enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy.
  • dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple
  • the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or ⁇ -hydroxylase inhibitors.
  • the decarboxylase inhibitor is selected from the group consisting of the following: D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
  • catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically acceptable salts thereof.
  • the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine, as well as physiologically acceptable salts thereof.
  • the hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
  • Another subject of the invention is the use of the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for the production of pharmaceuticals for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy.
  • dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple
  • Another subject of the present invention is a pharmaceutical composition which contains the deuterated catecholamines according to the invention as well as their physiologically acceptable salts for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, in addition to pharmaceutically acceptable adjuvants and additives.
  • dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of am
  • composition which contains the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for the treatment of Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating of the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, as well as one or more enzyme inhibitors, in addition to pharmaceutically acceptable adjuvants and additives.
  • a pharmaceutical composition is particularly preferred in which the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or ⁇ -hydroxylase inhibitors.
  • the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
  • the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,
  • composition in which the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as their physiologically acceptable salts.
  • the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically acceptable salts thereof.
  • ⁇ -hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
  • Another subject of the invention is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof for use in the prophylaxis of psychoses, particularly in predisposed patients, for the prophylaxis of a relapse and also particularly for the treatment of acute psychoses, for example, with negative symptomatology.
  • deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof, in combination with one or more enzyme inhibitors, for use in the prophylaxis of psychoses and for use in acute psychoses, preferably psychoses with negative symptomatology.
  • the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof, if the enzyme inhibitor or the enzyme inhibitors are decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or ⁇ -hydroxylase inhibitors.
  • the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
  • the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,
  • catechol-O-methyl-transferase inhibitor is selected from entacapone and cabergoline as well as physiologically acceptable salts thereof.
  • the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof is advantageous, if the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically acceptable salts thereof.
  • deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof is particularly advantageous, if the ⁇ -hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
  • Another subject of the invention is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof for the production of pharmaceuticals for use in the prophylaxis of psychoses.
  • Still another subject of the invention is a pharmaceutical composition which contains the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for use in the prophylaxis of psychoses and for the treatment of acute psychoses, in addition to pharmaceutically acceptable adjuvants and additives.
  • composition which contains the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for the prophylaxis of psychoses and for the therapy of acute psychoses as well as one or more enzyme inhibitors, in addition to pharmaceutically acceptable adjuvants and additives.
  • the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
  • the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), ( ⁇ )-L- ⁇ -hydrazino-3,4-dihydroxy- ⁇ -methylhydrocinnamic acid (carbidopa), L-serine 2-(2,
  • composition in which the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically acceptable salts thereof.
  • composition in which the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically acceptable salts thereof.
  • ⁇ -hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
  • physiologically acceptable salts of the deuterated catecholamine derivatives for the production of the physiologically acceptable salts of the deuterated catecholamine derivatives according to the invention, the usual physiologically acceptable inorganic and organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid can be used. Additional acids that can be used are described, for example, in Fort Whitneye der Arzneistoffforschung, Vol. 10, pp. 224-225, Birkhäuser Publishers, Basel and Stuttgart, 1966, and Journal of Pharmaceutical Sciences, Vol. 66, pp. 1-5 (1977).
  • the acid addition salts are usually obtained in a way known in and of itself by mixing the free base or solutions thereof with the corresponding acid or solutions thereof in an organic solvent, for example, a lower alcohol, such as methanol, ethanol, n-propanol or isopropanol or a lower ketone such as acetone, methyl ethyl ketone or methyl isobutyl ketone or an ether such as diethyl ether, tetrahydrofuran or dioxane.
  • an organic solvent for example, a lower alcohol, such as methanol, ethanol, n-propanol or isopropanol or a lower ketone such as acetone, methyl ethyl ketone or methyl isobutyl ketone or an ether such as diethyl ether, tetrahydrofuran or dioxane.
  • a lower alcohol such as methanol, ethanol, n-propanol or iso
  • the acid addition salts of the compounds according to the invention can be converted to the free base in a way known in and of itself, e.g., with alkalis or ion exchangers. Additional salts can be obtained from the free base by reaction with inorganic or organic acids, particularly those which are suitable for the formation of salts that can be employed therapeutically. These or also other salts of the new compound, such as, e.g., the picrate, may also serve for purification of the free base by converting the free base into a salt, separating this salt, and again releasing the base from the salt.
  • the subject of the present invention is also pharmaceuticals for oral, buccal, sublingual, nasal, rectal, subcutaneous, intravenous or intramuscular application as well as for inhalation, which, in addition to the usual vehicle and dilution agents, also contain a compound of general formula I or the acid addition salt thereof as an active ingredient.
  • the pharmaceuticals of the invention are produced, in the known way and with suitable dosage, with the usual solid or liquid vehicle substances or dilution agents and the usually used pharmaceutical-technical adjuvants corresponding to the desired type of application.
  • the preferred preparations consist of a form of administration which is suitable for oral application.
  • forms of administration include, for example, tablets, sucking tablets, film tablets, dragees, capsules, pills, powders, solutions, aerosols or suspensions or slow-release forms.
  • parenteral preparations such as injection solutions are also considered.
  • suppositories for example, have also been named as preparations.
  • Corresponding tablets can be obtained, for example, by mixing the active substance with known adjuvants, for example, inert dilution agents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, bursting agents such as corn starch or alginic acid, binders such as starches or gelantins, lubricants such as magnesium stearate or talc and/or agents for achieving a slow-release effect such as carboxypolymethylene, carboxymethylcellulose, cellulose acetate phthalate or polyvinyl acetate.
  • the tablets may also consist of several layers.
  • Dragees can also be produced correspondingly, for controlled or delayed release forms of preparation, by coating the cores produced analogously to the tablets with agents commonly used in dragee coatings, for example, polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the dragee envelope may also consist of several layers, wherein the adjuvants mentioned above in the case of tablets can be used.
  • Solutions or suspensions containing the active substance used according to the invention may additionally contain agents that improve taste, such as saccharin, cyclamate or sugar, as well as, e.g., taste enhancers such as vanilla or orange extract. They may also contain suspension adjuvants such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoate.
  • Capsules containing active substances can be produced, for example, by mixing the active substance with an inert vehicle such as lactose or sorbitol and encapsulating this mixture in gelatin capsules. Suitable suppositories can be produced, for example, by mixing with vehicle agents provided therefore, such as neutral fats or polyethylene glycol or derivatives thereof.
  • L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid is a selectively deuterated L-DOPA derivative with better pharmacokinetic and pharmacodynamic properties when compared to L-DOPA.
  • Administration of L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid to male Wistar rats increased dopamine in the striatum significantly more compared to non-deuterated L-DOPA.
  • L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid increased dopamine in the striatum significantly more than L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid, although the compound has less deuterium at the beta position of the side chain of its molecule (Example 15 and Table 1).
  • L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid reduces the striatal output of norepinephrine compared to L-DOPA
  • L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid does not block the formation of norepinephrine.
  • L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid has two advantages, it provides more dopamine and enough norepinephrine which has been shown to play an important role in compensating for the loss in dopaminergic function (Archer and Fredriksson, 2006, Neural Transm., 113(9): 1119-29; Cathala et al. 2002, Neuroscience, 115(4): 1059-65; Tong et al. 2006, Arch Neurol, 63(12): 1724-8).
  • L-DOPA methyl ester has been shown to function as a prodrug of L-DOPA.
  • L-DOPA methyl ester given orally or intraperitoneally was equivalent on a molar basis to L-DOPA.
  • therapeutic equivalence was not maintained with continuous intravenous infusion in Patients with Parkinson's disease exhibiting severe on-off phenomena.
  • the optimal infusion rate for L-DOPA methyl ester was 2.7 times that required for L-DOPA (Stocchi et al. 1992, Movement Disorders, 7: 249-256).
  • L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester is therapeutically equivalent to L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid during continuous intravenous infusion.
  • the product is transferred to the organic phase by extraction with oxygen-free ethyl acetate, which contains 0.01% 2,6-ditert-butyl-4-methoxyphenol.
  • the organic phase is dried and then the solvent is distilled off 50 ml of oxygen-free diethyl ether are added to the residue and after this material is left to stand overnight, the D,L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl)methyl propionate precipitates.
  • 1.8 g of product is isolated.
  • the deuterated amino acid contained in the solution is separated from the deuterated methyl ester chromatographically by use of the solvent system of acetonitrile/0.1% aqueous trifluoroacetic acid (15:85) and 0.51 g of L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid is isolated.
  • the product is transferred to the organic phase by extraction with oxygen-free ethyl acetate, which contains 0.01% 2,6-ditert-butyl-4-methoxyphenol.
  • the organic phase is dried and then the solvent is distilled off 50 ml of oxygen-free diethyl ether are added to the residue and after the material is left to stand overnight, the L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl)methyl propionate precipitates.
  • the product is transferred to the organic phase by extraction with oxygen-free ethyl acetate, which contains 0.01% 2,6-ditert-butyl-4-methoxyphenol.
  • the organic phase is dried and then the solvent is distilled off 50 ml of oxygen-free diethyl ether are added to the residue, and after the material is left to stand overnight, the L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl)ethyl propionate precipitates.
  • 2 g of product is isolated.
  • the compound is produced according to the description for the mono-deuterated compound (cf. example 4).
  • the compound is produced according to the description for the mono-deuterated compound (cf. example 5).
  • the compound is produced according to the description for the mono-deuterated compound (cf. example 4).
  • the compound is produced according to the description for the mono-deuterated compound (cf. example 5).
  • the compound is produced according to the description for the mono-deuterated compound (cf. example 4).
  • the compound is produced according to the description for the mono-deuterated compound (cf. example 5).
  • L-DOPA L-2-Amino-3-(3,4-dihydroxyphenyl) propionic acid
  • L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid WO-A 2004/056724, Example 6
  • L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid Example 6
  • Dialysis probes were implanted in the dorsolateral striatum (AP: +0.6: ML+3.0: DV ⁇ 6.2 relative to bregma and the dural surface according to the atlas of Paxinos and Watson (1998)). Dialysis occurs through a semipermeable membrane (Filtral AN69, Hospal Industrie, France) with an active surface length of 3.5 mm. Dialysis experiments were conducted approximately 48 h after surgery in freely moving rats. The rats received 30 min before administration of test items 10 mg/kg Carbidopa, (i.p.).
  • the dialysis probe was perfused with a physiological perfusion solution (Apoteksbolaget, Sweden) at a rate of 2.5 ml/min set by a microinfusion pump (Harvard Apparatus, Holliston, Mass.). Dialysate was collected over 15 min intervals and automatically injected into a high performance liquid chromatography (HPLC) system. On-line quantification of dopamine in the dialysate was accomplished by electrochemical detection (ESA, Chelmsford, Mass.). The location of microdialysis probes was verified in slices of formalin-fixed tissue stained with neutral red. The baseline corrected concentrations (fmol/min) were plotted over the time.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US14/464,568 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds Active 2029-07-01 USRE46555E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/464,568 USRE46555E1 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102006008316 2006-02-17
DE102006008316 2006-02-17
PCT/EP2007/001555 WO2007093450A2 (fr) 2006-02-17 2007-02-16 Derives de catecholamine deuteries et medicaments comprenant de tels composes
US14/464,568 USRE46555E1 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds
US12/224,120 US8247603B2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Publications (1)

Publication Number Publication Date
USRE46555E1 true USRE46555E1 (en) 2017-09-19

Family

ID=38236462

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/224,120 Ceased US8247603B2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds
US14/464,568 Active 2029-07-01 USRE46555E1 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/224,120 Ceased US8247603B2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Country Status (24)

Country Link
US (2) US8247603B2 (fr)
EP (2) EP3101001B1 (fr)
JP (1) JP5248331B2 (fr)
KR (1) KR101411422B1 (fr)
CN (1) CN101384545B (fr)
AU (1) AU2007214622B2 (fr)
BR (1) BRPI0708071A8 (fr)
CA (1) CA2642593C (fr)
CY (1) CY1117995T1 (fr)
DK (1) DK1991522T3 (fr)
EA (1) EA017983B1 (fr)
ES (1) ES2587368T3 (fr)
HR (1) HRP20161039T1 (fr)
HU (1) HUE028777T2 (fr)
IL (1) IL193102A (fr)
LT (1) LT1991522T (fr)
ME (1) ME02508B (fr)
PL (1) PL1991522T3 (fr)
PT (1) PT1991522T (fr)
RS (1) RS55142B1 (fr)
SI (1) SI1991522T1 (fr)
UA (1) UA97795C2 (fr)
WO (1) WO2007093450A2 (fr)
ZA (1) ZA200806568B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DK2303330T4 (da) 2008-06-06 2021-09-13 Pharma Two B Ltd Farmaceutiske sammensætninger til behandling af parkinsons sygdom
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
EP2819656A1 (fr) 2012-02-28 2015-01-07 Grünenthal GmbH Forme pharmaceutique inviolable comprenant un composé pharmacologiquement actif et un polymère anionique
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2013318182C1 (en) 2012-09-18 2022-01-20 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
KR20150115807A (ko) 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
US9763904B2 (en) 2013-02-05 2017-09-19 Teva Pharmaceuticals International Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
WO2014174425A2 (fr) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques
MX2016000219A (es) * 2013-07-08 2016-05-31 Auspex Pharmaceuticals Inc Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
CA2930167A1 (fr) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Methodes de traitement d'une activite musculaire anormale
NZ720301A (en) 2013-12-03 2022-01-28 Auspex Pharmaceuticals Inc Deuterated tetrabenazine compounds
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
EP2918266A1 (fr) 2014-03-11 2015-09-16 CDRD Berolina AB Composition contenant une agoniste du dopamine et un dérivé du L-Dopa pour le traitement de la maladie de Parkinson
GB201420341D0 (en) * 2014-11-17 2014-12-31 Evolution Valves Ltd Valve arrangement
KR20230003264A (ko) 2015-03-06 2023-01-05 오스펙스 파마슈티칼스, 인코포레이티드 비정상적 불수의 운동 장애의 치료 방법
CN106343013A (zh) * 2015-07-19 2017-01-25 中国科学院上海有机化学研究所 一种粮食储存方法
CN105360267B (zh) * 2015-10-09 2017-11-10 青岛振坤食品机械有限公司 一种全自动穿串机
TW201720443A (zh) 2015-10-09 2017-06-16 梯瓦製藥國際有限責任公司 用以治療帕金森氏症之經氘化左旋多巴、碳度巴、以及奧匹卡朋的組合
CN105862897B (zh) * 2016-04-11 2018-01-16 江苏省华建建设股份有限公司 砂质泥岩地基浅基础原槽浇筑施工工法
SG11202105545QA (en) * 2018-12-06 2021-06-29 Senda Biosciences Inc Quaternary ammonium salts as inhibitors of trimethylamine production

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
DE2049115A1 (en) 1970-10-06 1972-04-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokio 5-butyl-and5-pentyl-picolinic acids active - as dopamene-b-hydroxylase inhibitors
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
EP0357565A2 (fr) 1988-07-12 1990-03-07 Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica Procédé de préparation de levodopa
US5017607A (en) * 1986-06-10 1991-05-21 Chiesi Farmaceutici S.P.A. Method to treat Parkinsons disease
US5525631A (en) * 1992-12-24 1996-06-11 The Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of the ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6603008B1 (en) * 1999-12-03 2003-08-05 Pfizer Inc. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004056306A2 (fr) 2002-12-19 2004-07-08 Bdd Berolina Drug Development Gmbh Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
DE2049115A1 (en) 1970-10-06 1972-04-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokio 5-butyl-and5-pentyl-picolinic acids active - as dopamene-b-hydroxylase inhibitors
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
US5017607A (en) * 1986-06-10 1991-05-21 Chiesi Farmaceutici S.P.A. Method to treat Parkinsons disease
EP0357565A2 (fr) 1988-07-12 1990-03-07 Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica Procédé de préparation de levodopa
US4962223A (en) 1988-07-12 1990-10-09 Ministero dell'Universita e delle Ricerca Scientifica e Tecnologica Process for the synthesis of the levodopa
US5525631A (en) * 1992-12-24 1996-06-11 The Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of the ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6603008B1 (en) * 1999-12-03 2003-08-05 Pfizer Inc. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004056724A1 (fr) 2002-12-19 2004-07-08 Bdd Berolina Drug Development Gmbh Derives de catecholamines deuteres et medicaments contenant lesdits composes
WO2004056306A2 (fr) 2002-12-19 2004-07-08 Bdd Berolina Drug Development Gmbh Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques
US20060135615A1 (en) * 2002-12-19 2006-06-22 Rudolf-Giesbert Alken Deuterated catecholamine derivatives and medicaments comprising said compounds

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Clinical effect of l-dopa on schizophrenia" Ogura, Chikara; Kishimoto, Akira; Nakao, Takehisa Current Therapeutic Research, vol. 20(3), Sep. 1976, 308-318.
"Comparative metabolism of d- and l-3,4-dihydroxyphenylaline in normal and pyridoxine-deficient rats" T. L Sourkes, Miriam H. Wiseman-Distler, J. F. Moran, G. F. Murphy, and Simonne Saint Cyr Biochem J. Dec. 1964; 93(3): 469-474.
"Deuteriation and tritiation of aryl aldehydes in the formyl group and the synthesis of (±)-3,4-dihydroxy[β-2H2] phenylalanine" D.J. Bennett, G.W. Kirby, and V.A. Moss, J. Chem Soc. C: Organic , 1970, 2049-2051.
"Facile preparation of optically pure [α-2H]-α-amino acids" Shui-Tein Chen, Chen-Chen Tu, and Kung-Tsung Wang Biotechnology Letters vol. 14 No. 4 (Apr. 1992) pp. 269-274.
"Studies on the phenylalanine hydroxylase system in vivo. An in vivo assay based on the liberation of deuterium or tritium into the body water from ring-labeled L-phenylalanine" Sheldon Milstien and Seymour Kaufman J. Biol. Chem. 1975 250: 4782-4785.
"Studies related to the Chemistry of Melanins. Part IX. Synthesis of Specifically Deuterated 3,4-Dihydroxyphenylamines and (+/−)-3,4-Dihydroxyphenylalanines" F. Binns, J. A. G. King, A. Percival, N. C. Robson and G. A. Swan, J. Chem Soc. C: Organic, 1970, 1134-1138.
Claffey et al. Chem. Res. Toxicol. 2001, 14, 1339-1334. *
Dewar et al. Neuro-Psychopharmacology & Biological Psychiatry 1985, 9(5-6), 675-680. *
Dewar et al., "Changes in Brain Catecholamine Levels Following DL-Dopa are not Potentiated by Deuterium Substitution," Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 9:675-80 (1985).
Dyck et al., "Effects of Deuterium Substitution on the Catabolism of β-Phenylethylamine: An In Vivo Study", Journal of Neurochemistry, vol. 46, Issue 2, pp. 399-404, Feb. 1986.
Edwards, et al., Conversion of 3, 4-Dihydroxyphenylalanine and Deuterated 3, 4-Dihydroxyphenylalanine to Alcoholic Metabolites of Catecholamines in Rat Brain, J. Neurochem, May 1981;36(5):1641-7.
Gouyette, A., "Synthesis of Deuterium-Labelled Elliptinium and its Use in Metabolic Studies", Biomedical & Environmental Mass Spectrometry, vol. 15, Issue 5, pp. 243-247, Mar. 1988.
Haskins, Biomedical Spectrometry vol. 9 Issue 7, pp. 269-277, 1982.
Hayashi et al., "Analysis of L-DOPA in vivo Kinetics by the Stable Isotope Tracer Method", Proceedings of Japanese Society for Biomedical Mass Spectrometry, 13, (9) 1988, 229-232.
Kushner, etal., "Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds," Can. J. Physiol. Pharmacol. , 77:79-88 (1999).
Oba et al. "Stereo-divergent Synthesis of L-threo- and L-erythro-[2,3-2H2] amino acids using optically active dioxopiperazine as a chiral template" J. Chem. Soc., Perkin Trans. 1, Jan. 1998.
Stark et al., "Quantitative Analysis of N-Phenylpropenoyl-l-amino Acids in Roasted Coffee and Cocoa Powder by Means of a Stable Isotope Dilution Assay," J. Agric. Food Chem., 2006, 54 (8), pp. 2859-2867.
Tonn et al., "Simultaneous analysis of diphenhydramine and a stable isotope analog (2H10)diphenhydramine using capillary gas chromatography with mass selective detection in biological fluids from chronically instrumented pregnant ewest†", Biological Mass Spectrometry, vol. 22, Issue 11, pp. 633-642, 1993.
Vining et al., "Deuterium Exchange Labelling of Biologically Important Phenols, Indoles and Steroids", Journal of Labelled Compounds and Radiopharmaceuticals, vol. 18, Issue 11, pp. 1683-1692, Nov. 1981.
Weiner et al. Neurology, 2000, 54(7), p. 1538. *
Wolen, "The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence", The Journal of Clinical Pharmacology, vol. 26, Issue 6, pp. 419-424, Jul.-Aug. 1986.
Yu Biochemistry and Cell biology, 1988, v66(8), 853-861. *
Yu et al., "Stereospecific Deuterium Substitution at the Alpha-Carbon Position of Dopamine and its Effect on Oxidative Deamination Catalyzed by MAO-A and MAO-B from Different Tissues", Biochem Pharmacol. Mar. 15, 1986;35 (6):1027-36.

Also Published As

Publication number Publication date
KR20080106539A (ko) 2008-12-08
CN101384545B (zh) 2014-09-03
KR101411422B1 (ko) 2014-07-03
RS55142B1 (sr) 2016-12-30
CA2642593A1 (fr) 2007-08-23
PT1991522T (pt) 2016-08-23
BRPI0708071A8 (pt) 2017-12-26
US20090018191A1 (en) 2009-01-15
LT1991522T (lt) 2016-09-26
EP3101001A1 (fr) 2016-12-07
CY1117995T1 (el) 2017-05-17
PL1991522T3 (pl) 2017-07-31
US8247603B2 (en) 2012-08-21
HRP20161039T1 (hr) 2016-11-04
EA200801826A1 (ru) 2009-02-27
EP1991522A2 (fr) 2008-11-19
CA2642593C (fr) 2014-11-04
ES2587368T3 (es) 2016-10-24
IL193102A (en) 2015-01-29
EA017983B1 (ru) 2013-04-30
AU2007214622B2 (en) 2012-02-23
SI1991522T1 (sl) 2016-10-28
EP3101001B1 (fr) 2020-04-01
IL193102A0 (en) 2009-02-11
UA97795C2 (uk) 2012-03-26
HUE028777T2 (en) 2017-01-30
JP5248331B2 (ja) 2013-07-31
JP2009526799A (ja) 2009-07-23
EP1991522B1 (fr) 2016-05-18
WO2007093450A2 (fr) 2007-08-23
WO2007093450A3 (fr) 2007-09-27
AU2007214622A1 (en) 2007-08-23
DK1991522T3 (en) 2016-08-29
ZA200806568B (en) 2009-07-29
ME02508B (fr) 2017-06-20
BRPI0708071A2 (pt) 2011-05-17
CN101384545A (zh) 2009-03-11

Similar Documents

Publication Publication Date Title
USRE46555E1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
US7462737B2 (en) Pregabalin free of isobutylglutaric acid and a process for preparation thereof
EP0610595A2 (fr) Composition d'esters du L-dopa
JP2018193356A (ja) 重水素化カテコールアミン誘導体ならびにそれらの化合物を含有する医薬品
US20220000814A1 (en) Methods for treatment of prader-willi syndrome

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMPHAR AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH & DEVELOPMENT SERVICES;REEL/FRAME:035255/0900

Effective date: 20150130

AS Assignment

Owner name: RATIOPHARM GMBH, GERMANY

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:IMPHAR AKTIENGESELLSCHAFT;RATIOPHARM GMBH;REEL/FRAME:039552/0001

Effective date: 20160614

AS Assignment

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH, SWITZERLA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RATIOPHARM GMBH;REEL/FRAME:041420/0200

Effective date: 20170222

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY